Search

everythinglearnresearchcommunity

for

Search:↓

A new painless microneedle patch shows promise in reversing hair loss. The discussion focuses on potential new treatments beyond common options like Minoxidil, finasteride, and RU58841.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

User considers trying RU58841 for hair loss and asks for advice on its effectiveness and application. Responses vary, with some reporting positive results and others warning about potential risks or lack of change.

Ashwagandha topical formulation may increase hair density and reduce hair loss, but results seem too good to be true due to a small sample size. Users are skeptical about its effectiveness and are experimenting with different application methods.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

The user is experimenting with a mix of topical treatments, including finasteride and minoxidil, to improve hair growth, particularly at the temples and core. They are also trying various oils, despite skepticism about their effectiveness, to see if they can enhance results without causing harm.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

A user offers an extra bottle of Koshine 0.5% solution for hair loss. The discussion involves interest in trying Pyrilutamide for hair treatment.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The conversation humorously acknowledges the role of mice in testing Minoxidil for hair loss while also discussing the ethics of animal testing. Some users argue against animal testing, citing cruelty, while others defend its necessity for medical advancements.

The conversation discusses creating a topical hair loss treatment by dissolving melatonin in ethanol and possibly mixing it with castor oil, questioning the stability of the solution. An alternative of using glycerin is also considered.

A user tried BeauTop (Primal Hair) for hair loss, alongside a topical blend of finasteride, rapamycin, and caffeine, and noticed positive results. They cannot confirm BeauTop is the sole reason for improvement and are curious about others' experiences.

RU58841 mixed with Minoxidil seems less effective over time, so the user plans to switch to a PG and Ethanol dilution for better results. They also consider using rosemary oil with Minoxidil to enhance RU58841 absorption.

A user is experimenting with applying undiluted peppermint oil to their scalp daily to stimulate hair growth, based on a rat study where peppermint oil outperformed minoxidil. The user reports immediate hair thickening and increased scalp blood flow, while others in the conversation express skepticism, humor, and concern about the undiluted application.

The conversation discusses the potential positive effects of melatonin on hair growth. The original poster plans to try both oral and topical melatonin and is seeking recommendations for a good source.

Kintor is testing Pyrilutamide with Minoxidil for hair loss. Users are skeptical about its effectiveness and concerned about limited treatment options if this fails.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.

The conversation discusses using a multimodal approach to treat androgenic alopecia, including substances like gamma-linolenic acid, DHA, sulforaphane, melatonin, cetirizine, astaxanthin, fisetin, apigenin, curcumin, limonene, genistein, and berberine. Users also mention using ketoconazole, minoxidil, and low-level laser therapy (LLLT) as part of their hair loss treatment regimens.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

A 19-year-old plans to use an experimental hair loss treatment stack including micro-needling, Minoxidil, Pyrilutamide, Ketoconazole shampoo, and other unreleased compounds like PP405. Users advise against using unverified treatments and suggest sticking to proven options like Finasteride, with some recommending topical application to avoid side effects.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.